Coatable transdermal delivery microprojection assembly

• US 20070293814A1
• Filed: 09/11/2006
• Published: 12/20/2007
• Est. Priority Date: 09/12/2005
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Tong, Ling-Kang, Trautman, Joseph, Donnelly, Doran
• Application Number:
  US11/518,970
• Publication Number:
  US 20070293814A1
• Time in Patent Office: Days
• US Class Current: 604/46
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0046 Solid microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles

Abstract

The present invention is a transdermal delivery microprojection assembly that includes a microprojection member secured to a retainer adapted for use with an impact applicator wherein at least a portion of the microprojections extend beyond a plane formed by the end of the retainer. The configuration allows a biocompatible coating containing a biologically active agent to be applied to the microprojection member after it is mounted on the retainer. The present invention minimizes the number of manufacturing steps that must be carried out under aseptic conditions to maintain sterility of the assembly after the coating is applied to the microprojection member.

Claims

1. A transdermal delivery assembly, comprising:

a microprojection member having top and bottom surfaces and a plurality of stratum corneum-piercing microprojections that project from said bottom surface of said microprojection member; and

a retainer having first and second ends and a central opening;

wherein said microprojection member is secured to said retainer within said central opening and wherein said microprojection member is positioned adjacent said first end of said retainer so that at least a portion of said microprojections extend beyond a plane formed by said first end of said retainer.

2. The assembly of claim 1, further comprising an adhesive patch, wherein said microprojection member is secured to said patch and said patch is secured to said retainer.

3. The assembly of claim 2, wherein said patch is secured to said retainer by frangible tabs.

4. The assembly of claim 2, wherein said patch has first and second sides and wherein said microprojection member is secured to said first side.

5. The assembly of claim 4, wherein said patch is secured to said retainer by an adhesive on said first side.

6. The assembly of claim 4, wherein said patch is secured to said retainer by an adhesive on said second side.

7. The assembly of claim 2, wherein said first end of said retainer is configured to nest with said second end of said retainer so that a plurality of retainers can be stacked.

8. The assembly of claim 7, wherein said microprojection member is secured to said retainer so that said microprojection member does not contact adjacent microprojection members and adhesive patches when a plurality of assemblies are stacked.

9. The assembly of claim 1, further comprising a housing having first and second ends and a central opening, wherein said housing is adapted to receive and position said retainer within said central opening of said housing and wherein said retainer is disposed within said housing.

10. The assembly of claim 9, wherein said first end of said housing is adapted to releasably attach to an impact applicator.

11. The assembly of claim 9, wherein said retainer is positioned within said housing so that said microprojection member is spaced away from said first and second ends of said housing.

12. The assembly of claim 1, further comprising a biologically active agent disposed on said microprojections in a biocompatible coating.

13. The assembly of claim 12, wherein said active agent is selected from the group consisting of growth hormone release hormone (GHRH), growth hormone release factor (GHRF), insulin, insultropin, calcitonin, octreotide, endorphin, TRN, NT-36 (chemical name:

N-[[(s)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide), liprecin, pituitary hormones, hGH, HMG, desmopressin acetate, follicle luteoids, aANF, growth factors, growth factor releasing factor (GFRF), bMSH, GH, somatostatin, bradykinin, somatotropin, platelet-derived growth factor releasing factor, asparaginase, bleomycin sulfate, chymopapain, cholecystokinin, chorionic gonadotropin, erythropoietin, epoprostenol (platelet aggregation inhibitor), gluagon, HCG, hirulog, hyaluronidase, interferon alpha, interferon beta, interferon gamma, interleukins, interleukin-10 (IL-10), erythropoietin (EPO), amylin, insulinotropin, GLIP1, granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), glucagon, leutinizing hormone releasing hormone (LHRH), LHRH analogs (such as goserelin, leuprolide, buserelin, triptorelin, gonadorelin, and napfarelin, menotropins (urofollitropin (FSH) and LH)), oxytocin, streptokinase, tissue plasminogen activator, urokinase, vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, desmopressin, corticotropin (ACTH), ACTH analogs, ACTH (1-24), ANP, ANP clearance inhibitors, angiotensin II antagonists, antidiuretic hormone agonists, bradykinn antagonists, ceredase, CSI'"'"'s, calcitonin gene related peptide (CGRP), enkephalins, FAB fragments, IgE peptide suppressors, IGF-1, neurotrophic factors, colony stimulating factors, parathyroid hormone and agonists, parathyroid hormone antagonists, parathyroid hormone (PTH), PTH analogs, prostaglandin antagonists, pentigetide, protein C, protein S, renin inhibitors, thymosin alpha-1, thrombolytics, TNF, vasopressin antagonists analogs, alpha-1 antitrypsin (recombinant), TGF-beta, alpha MSH, VEGF, PYY and hBNP.

14. The assembly of claim 12, wherein said active agent is an immunologically active agent selected from the group consisting of proteins, polysaccharide conjugates, oligosaccharides, lipoproteins, tetanus toxoid, diphtheria toxoid, botulinum toxoid, hemaglutinins, hepatitis B surface antigen, Bordetella pertussis (recombinant PT accince-acellular), Clostridium tetani (purified, recombinant), Corynebacterium diphtheriae (purified, recombinant), Cytomegalovirus (glycoprotein subunit), Group A streptococcus (glycoprotein subunit, glycoconjugate Group A polysaccharide with tetanus toxoid, M protein/peptides linked to toxing subunit carriers, M protein, multivalent type-specific epitopes, cysteine protease, C5a peptidase), Hepatitis B virus (recombinant Pre 51, Pre-S2, S, recombinant core protein), Hepatitis C virus (recombinant—

expressed surface proteins and epitopes), Human papillomavirus (Capsid protein, TA-GN recombinant protein L2 and E7 [from HPV-6], MEDI-501 recombinant VLP L1 from HPV-11, Quadrivalent recombinant BLP L1 [from HPV-6], HPV-11, HPV-16, and HPV-18, LAMP-E7 [from HPV-16]), Legionella pneumophila (purified bacterial surface protein), Neisseria meningitides (glycoconjugate with tetanus toxoid), Pseudomonas aeruginosa (synthetic peptides), Rubella virus (synthetic peptide), Streptococcus pneumoniae (glyconconjugate [1, 4, 5, 6B, 9N, 14, 18C, 19V, 23F] conjugated to meningococcal B OMP, glycoconjugate [4, 6B, 9V, 14, 18C, 19F, 23F] conjugated to CRM197, glycoconjugate [1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F] conjugated to CRM1970, Treponema pallidum (surface lipoproteins), Varicella zoster virus (subunit, glycoproteins), and Vibrio cholerae (conjugate lipopolysaccharide).

15. The assembly of claim 12, wherein said biocompatible coating further comprises at least one vasoconstrictor.

16. The assembly of claim 12, wherein said biocompatible coating further comprises at least one pathway patency modulator.

17. A method for producing a transdermal delivery assembly, comprising the steps of:

providing a microprojection member having top and bottom surfaces and a plurality of stratum corneum-piercing microprojections that project from said bottom surface of said microprojection member;

providing a retainer having first and second ends and a central opening; and

securing said microprojection member to said retainer within said central opening to form said transdermal delivery assembly wherein said microprojection-member is positioned adjacent said first end of said retainer so that at least a portion of said microprojections extend beyond a plane formed by said first end of said retainer.

18. The method of claim 17, further comprising the step of providing an adhesive patch, wherein the step of securing said microprojection member to said retainer comprises securing said microprojection member to said patch and securing said patch to said retainer.

19. The method of claim 18, further comprising the step of sterilizing said transdermal delivery assembly.

20. The method of claim 19, further comprising the step of applying a biocompatible coating containing at least one biologically active agent to said microprojection member after said transdermal delivery assembly is sterilized.

21. The method of claim 20, wherein said step of applying a biocompatible coating comprises roller coating.

22. The method of claim 20, wherein said step of applying a biocompatible coating comprises dip-coating.

23. The method of claim 20, further comprising the steps of providing a housing having first and second ends and a central opening, wherein said housing is adapted to receive and position said retainer within said central opening of said housing and placing said retainer within said housing after applying said biocompatible coating.